Lv3
236 积分 2022-01-04 加入
Evolution of claudin18.2 therapies in gastroesophageal cancers
5天前
已完结
The genomic landscape of pediatric acute lymphoblastic leukemia
12天前
已完结
Jian Zhou: champion of liver cancer prevention and treatment
13天前
已完结
Daratumumab-Bortezomib-Thalidomide-Dexamethasone for Newly Diagnosed Myeloma: CASSIOPEIA Minimal Residual Disease Results
16天前
已关闭
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial
18天前
已完结
Acute lymphocytic leukaemia
21天前
已完结
How I treat acute lymphoblastic leukemia in the era of immunotherapy while revisiting the myth of second remission
23天前
已完结
Splenectomy
23天前
已关闭
US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor–Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2–Low or Human Epidermal Growth Factor Receptor 2–Ultralow Breast Cancer
24天前
已关闭
Final analysis results and patient-reported outcomes from DESTINY-Lung02—a dose-blinded, randomized, phase 2 study of trastuzumab deruxtecan in patients with HER2-mutant metastatic non–small cell lung cancer
27天前
已完结
皖公网安备34019202002308
